Product Overview
Ozagrel Sodium (CAS: 189224-26-8) is a sodium salt form of Ozagrel, a selective thromboxane A2 synthase inhibitor with the molecular formula C₁₃H₁₁N₂NaO₂ (MW: 250.23). It effectively reduces platelet aggregation and vasoconstriction by blocking thromboxane A2 synthesis, making it a critical agent for treating cerebral thrombosis and acute ischemic stroke. Available as a white crystalline powder, it is widely utilized in clinical and pharmaceutical research for thrombosis-related therapies.
✨ Key Advantages
✅ High Purity: ≥99% (HPLC/GC verified), ensuring pharmaceutical-grade compliance.
✅ Targeted Action: IC₅₀ of 4 nM against thromboxane A2 synthase, offering precise therapeutic effects.
✅ Stable Storage: Maintains integrity at 2–8°C (protected from light) or -20°C for long-term preservation.
🔬 Application Fields
Clinical Treatment: Primary use in managing cerebral thrombosis and ischemic cerebrovascular diseases.
Mechanistic Research: Study of platelet aggregation pathways and thromboxane-related pathologies.
Drug Development: Intermediate for synthesizing advanced antithrombotic medications.
📜 Quality Certifications
Manufactured in GMP-certified facilities, compliant with USP/EP/BP standards.
Rigorously tested via HPLC, NMR, and mass spectrometry for identity and purity.
Adheres to MSDS guidelines for safe handling, storage, and transportation.
📈 Market Insights
The global antithrombotic drug market is projected to reach $45.7B by 2030 (CAGR 6.8%), driven by rising cardiovascular disease prevalence and demand for targeted therapies. Ozagrel Sodium’s efficacy in acute thrombotic events positions it as a vital therapeutic option.
China
